Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is a paper indexed in PICO Portal from OpenAlex.
How many citations does Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib have?
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib has 418 citations in the OpenAlex counts PICO Portal stores.
When was Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib published?
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib has 2019 year in the PICO Portal index.
What is the open-access status of Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib has bronze oa status in the PICO Portal index.
What is the DOI of Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?
The DOI for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is on the source record.
What is the PMID of Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?
The PMID for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is on the source record.
What is the OpenAlex record for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?
The OpenAlex for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is on the source record.